Last reviewed · How we verify
Myfortic Escalation
Myfortic (mycophenolate sodium) is an inosine monophosphate dehydrogenase (IMPDH) inhibitor that suppresses T and B lymphocyte proliferation to prevent organ rejection.
Myfortic (mycophenolate sodium) is an inosine monophosphate dehydrogenase (IMPDH) inhibitor that suppresses T and B lymphocyte proliferation to prevent organ rejection. Used for Prevention of acute organ rejection in adult patients receiving allogeneic renal transplants (as part of combination immunosuppressive regimen).
At a glance
| Generic name | Myfortic Escalation |
|---|---|
| Also known as | Enteric-coated mycophenolate sodium |
| Sponsor | East Carolina University |
| Drug class | Inosine monophosphate dehydrogenase (IMPDH) inhibitor |
| Target | IMPDH type II |
| Modality | Small molecule |
| Therapeutic area | Immunology |
| Phase | FDA-approved |
Mechanism of action
Myfortic selectively inhibits IMPDH type II, an enzyme critical for guanosine nucleotide synthesis in lymphocytes. By depleting guanosine nucleotides, it preferentially suppresses proliferation of T and B cells while sparing other cell types, thereby reducing the immune response against transplanted organs. The escalation formulation refers to dose titration protocols used in transplant maintenance therapy.
Approved indications
- Prevention of acute organ rejection in adult patients receiving allogeneic renal transplants (as part of combination immunosuppressive regimen)
Common side effects
- Diarrhea
- Nausea
- Vomiting
- Abdominal pain
- Infection
- Leukopenia
- Anemia
Key clinical trials
- Pilot Trial of Allogeneic Blood or Marrow Transplantation for Primary Immunodeficiencies (PHASE2)
- The Lowest Effective Dose of Post-Transplantation Cyclophosphamide in Combination With Sirolimus and Mycophenolate Mofetil as Graft-Versus-Host Disease Prophylaxis After Reduced Intensity Conditioning and Peripheral Blood Stem Cell Transplantation (PHASE1, PHASE2)
- A Dose Escalation Study of TCD601 Compared to ATG in de Novo Renal Transplantation (PHASE2)
- Donor Lymphocyte Infusion After Allogeneic Hematopoietic Cell Transplantation for High-Risk Hematologic Malignancies (PHASE1, PHASE2)
- Phase I Study of CTL Anti-DP Infusion Post-hematopoietic Stem Cell Transplantation (PHASE1)
- Phase I Trial Integrating HLA-Haploidentical Anti-CD19 CAR-T Cells With Post-Transplantation Cyclophosphamide-Based HLA-Haploidentical Hematopoietic Cell Transplantation (PHASE1)
- Universal CAR-T Cells (REVO-UWD-03) for Advanced Hepatocellular Carcinoma and Lung Cancer (EARLY_PHASE1)
- Mycophenolate Mofetil in Combination With Standard of Care for the Treatment of Glioblastoma (PHASE1)
Primary sources
Every claim on this page is sourced from regulatory or scientific primary sources. See our editorial policy for full methodology.
| Source | Used for |
|---|---|
| ClinicalTrials.gov | Trial enrolment, design, endpoints, results |
Competitive intelligence
For the full competitive landscape — auto-detected comparators, recent regulatory actions across the set, upcoming PDUFA, patent timeline, sponsor landscape:
- Myfortic Escalation CI brief — competitive landscape report
- Myfortic Escalation updates RSS · CI watch RSS
- East Carolina University portfolio CI